Paid Clinical Trials Wyoming
Discover 33 paid clinical trials in Wyoming. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Amlitelimab with CorticosteroidsA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Sponsor:
Sanofi
Location:
Code:
NCT06241118
Conditions
Dermatitis Atopic
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Amlitelimab
Placebo
Topical corticosteroids
Topical tacrolimus or pimecrolimus
Physical ActivitySustaining Physical Activity After Cancer Exercise Sessions
Sponsor:
Colorado State University
Location:
Code:
NCT06359210
Conditions
Exercise Oncology
Physical Activity Behavior
Behavior Change Interventions
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Responder Monthly Behavior Change Discussion Sessions
Incomplete Responder Monthly Behavior Change Discussion Sessions
Incomplete Responder Monthly Behavior Change Discussion Sessions + Bi-Weekly Exercise Sessions
ExerciseAcute Effects of Exercise in College Students With ADHD
Sponsor:
University of Wyoming
Location:
Code:
NCT03666416
Conditions
Attention Deficit Hyperactivity Disorder
Effects of; Exertion
Working Memory
Change in Sustained Attention
Eligibility Criteria
Sex: All
Age: 18 - 29
Healthy Volunteers: Accepted
Interventions
Sprint Interval Training
Genetic StudiesMolecular Genetics Studies of Cancer Patients and Their Relatives
Sponsor:
City of Hope Medical Center
Location:
Code:
NCT04185935
Conditions
Malignant Neoplasm
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Accepted
Interventions
Biospecimen Collection
Questionnaire Administration
Bimatoprost & LUMIGANBioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Sponsor:
Amneal Pharmaceuticals, LLC
Location:
Code:
NCT05401357
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution
Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Visceral AdiposityEvaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth Program
Sponsor:
20Lighter
Location:
Code:
NCT05219240
Conditions
Obesity
Cardiovascular Diseases
Metabolic Syndrome
Metabolic Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
20Lighter Program
Access SupportNavigation and Parent Peer Support to Promote Access
Sponsor:
University of Colorado, Denver
Location:
Code:
NCT04029220
Conditions
Mental Disorder, Child
Mental Health
Family Health
Eligibility Criteria
Sex: All
Age: 1 - 70+
Healthy Volunteers: Accepted
Interventions
Parent Peer Navigation
Telehealth InterventionTelehealth Allied Health Care With People Who Have Parkinson's Disease Living in Rural Nevada and Wyoming
Sponsor:
University of Wyoming
Location:
Code:
NCT03381898
Conditions
Parkinson Disease
Eligibility Criteria
Sex: All
Age: 30+
Healthy Volunteers: Not accepted
Interventions
Telehealth Exercise, speech therapy, medication management
BiomarkersUsing Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT04462406
Conditions
Advanced Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Melanoma of Unknown Primary
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ipilimumab
Nivolumab
Patient Observation
Pembrolizumab
Daratumumab, Bortezomib, Lenalidomide, DexamethasoneTesting the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT04566328
Conditions
Plasma Cell Myeloma
RISS Stage I Plasma Cell Myeloma
RISS Stage II Plasma Cell Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bortezomib
Daratumumab and Hyaluronidase-fihj
Dexamethasone
Lenalidomide
Quality-of-Life Assessment